EGFR and neoplasm: Cetuximab is a promising agent that targets epidermal growth factor receptor (EGFR) and has shown an impressive ability to improve the tumor response and increase progression-free survival (PFS) and overall survival (OS) among patients with all RAS wild-type mCRC [4–6].